{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T11:07:18Z","timestamp":1649156838008},"reference-count":4,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chest"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1378\/chest.126.2.657","type":"journal-article","created":{"date-parts":[[2004,8,9]],"date-time":"2004-08-09T21:58:38Z","timestamp":1092088718000},"page":"657-658","source":"Crossref","is-referenced-by-count":0,"title":["Is the Recommendation Not To Use Rifampin Plus Pyrazinamide for Latent Tuberculosis Treatment Always Imperative?"],"prefix":"10.1016","volume":"126","author":[{"given":"Angelo","family":"Cazzadori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Allegranzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Scardigli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavio","family":"Favari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ercole","family":"Concia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1378\/chest.126.2.657_bib1","first-page":"735","article-title":"Update: adverse event data and revised American Thoracic Society\/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003","volume":"52","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1378\/chest.126.2.657_bib2","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1056\/NEJMsa021099","article-title":"Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States","volume":"347","author":"Khan","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.126.2.657_bib3","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1183\/09031936.02.00261402","article-title":"European framework for tuberculosis control and elimination in countries with a low incidence","volume":"19","author":"Broekmans","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.126.2.657_bib4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1183\/09031936.03.00047402","article-title":"Monitoring the quality of laboratories and the prevalence of resistance to antituberculosis drugs: Italy, 1998\u20132000","volume":"21","author":"Migliori","year":"2003","journal-title":"Eur Respir J"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215311946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215311946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T01:57:11Z","timestamp":1549331831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369215311946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":4,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["S0012369215311946"],"URL":"https:\/\/doi.org\/10.1378\/chest.126.2.657","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2004,8]]}}}